series-a-funding
(3)
Sudheesh Nair
Sudheesh Nair is the cofounder and CEO of TinyFish, a Palo Alto company building enterprise web agents that let AI navigate, research, and extract data from the web at scale. He grew up in a lower-middle-class family in a small town in India before a teacher's nudge toward a campus interview set him on a path to the United States. He was an early employee and president of Nutanix, where he helped scale the company from zero to more than $1 billion in revenue and a 2016 IPO, then served as CEO of ThoughtSpot, steering it from on-premises BI to a cloud-native AI analytics platform. In 2024 he cofounded TinyFish, which launched publicly in 2025 with $47 million in funding and counts Google among its early customers.
Tara Nickerson
Tara Nickerson, PhD, is President, CEO and Director of Therini Bio, a clinical-stage biopharmaceutical company developing fibrin-targeting immunotherapies for neurological and retinal diseases. A biopharma executive with more than 20 years of experience, she was a founding-team member and Chief Business Officer at both Maze Therapeutics and Prothena Corporation before taking the top job at Therini in 2024. She combines a research background from McGill University with an MBA from UC Berkeley's Haas School and a long track record of company-building, financing and dealmaking in the life sciences.
Richard Law
Richard Law is the Chief Business Officer of HAYA Therapeutics, the Lausanne- and San Diego-based biotech decoding the 'dark genome' to build RNA-guided medicines that reprogram disease-driving cell states. A computational chemist turned dealmaker with a Oxford PhD in molecular biophysics and an Imperial MBA, he spent over a decade at Evotec, then steered Exscientia through its 2021 Nasdaq IPO, marquee pharma partnerships, and 2024 merger with Recursion before joining HAYA in March 2025 to drive its partnering strategy and growth.